Target Information
General Information of This Target
| Target ID | PATR0CMGNI |
|||||
|---|---|---|---|---|---|---|
| Target Name | Protein cereblon (CRBN) |
|||||
| Gene Name | CRBN |
|||||
| Gene ID | ||||||
| Synonym | AD-006 |
|||||
| Sequence |
MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYL
GADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTF AVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQA KVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSW PRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLK IGSAIQRLRCELDIMNKCTSLCCKQCQETEITTKNEIFSLSLCGPMAAYVNPHGYVHETL TVYKACNLNLIGRPSTEHSWFPGYAWTVAQCKICASHIGWKFTATKKDMSPQKFWGLTRS ALLPTIPDTEDEISPDKVILCL Click to Show/Hide
|
|||||
| Family | the CRBN family |
|||||
| Function |
Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteinssuch as MEIS2 or ILF2. Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. Maintains presynaptic glutamate release and consequently cognitive functionssuch as memory and learningby negatively regulating large-conductance calcium-activated potassium (BK) channels in excitatory neurons. Likely to function by regulating the assembly and neuronal surface expression of BK channels via its interaction with KCNT1. May also be involved in regulating anxiety-like behaviors via a BK channel-independent mechanism. Plays a negative role in TLR4 signaling by interacting with TRAF6 and ECSITleading to inhibition of ECSIT ubiquitinationan important step of the signaling.
Click to Show/Hide
|
|||||
| Uniprot Entry | ||||||
| HGNC ID | ||||||
| KEGG ID | ||||||
Full List of The ADC Related to This Target
Investigative
| ADC Info | ADC Name | Antibody | Antigen | Payload | Linker | Ref |
|---|---|---|---|---|---|---|
Gemtuzumab-Compound (Ie) |
Gemtuzumab |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Gemtuzumab-Compound (Ie) linker |
[1] | |
Rituximab-Compound (la) DAR 8 |
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
NeoDegrader P1 |
Rituximab-Compound (la) linker |
[2] | |
Pertuzumab-Compound(la) |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P1 |
Pertuzumab-Compound(la) linker |
[2] | |
Trastuzumab-Compound (la) DAR 1.6 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P1 |
Trastuzumab-Compound (la) DAR 1.6 linker |
[2] | |
Trastuzumab-Compound (la) DAR 8 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P1 |
Trastuzumab-Compound (la) DAR 8 linker |
[2] | |
Pertuzumab-Compound (la) DAR 8 |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P1 |
Pertuzumab-Compound (la) DAR 8 linker |
[2] | |
OR000213-Compound (Ia) |
OR000213 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
OR000213-Compound (Ia) linker |
[2] | |
HuMy9-6IgG1-Compound (la) DAR 8 |
huMy9-6 IgG1 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
huMy9-6IgG1-Compound (la) DAR 8 linker |
[2] | |
Lintuzumab IgG1-Compound (la) DAR 8 |
Lintuzumab |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Lintuzumab IgG1-Compound (la) DAR 8 linker |
[2] | |
OR000213-Compound(la) DAR 8 |
OR000213 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
OR000213-Compound(la) DAR 8 linker |
[2] | |
HuMy9-6 IgG1-Compound (la) DAR 1.9 |
huMy9-6 IgG1 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
huMy9-6 IgG1-Compound (la) DAR 1.9 linker |
[2] | |
HuMy9-6IgG1-Compound (la) DAR3.9 |
huMy9-6 IgG1 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
huMy9-6IgG1-Compound (la) DAR3.9 linker |
[2] | |
HuMy9-6IgG1-Compound(la) DAR 5.5 |
huMy9-6 IgG1 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
huMy9-6IgG1-Compound(la) DAR 5.5 linker |
[2] | |
OR000213-Compound (la) DAR 1.2 |
OR000213 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
OR000213-Compound (la) DAR 1.2 linker |
[2] | |
OR000213-Compound(la) DAR 1.8 |
OR000213 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
OR000213-Compound(la) DAR 1.8 linker |
[2] | |
OR000213-Compound(la) DAR 2.3 |
OR000213 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
OR000213-Compound(la) DAR 2.3 linker |
[2] | |
Trastuzumab-Compound (Ib) DAR1.5 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P3 |
Trastuzumab-Compound (Ib) DAR1.5 linker |
[2] | |
Trastuzumab-Compound (lc) |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P4 |
Trastuzumab-Compound (lc) linker |
[2] | |
Rituximab-Compound (lc) |
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
NeoDegrader P4 |
Rituximab-Compound (lc) linker |
[2] | |
Pertuzumab-Compound(lc) |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P4 |
Pertuzumab-Compound(lc) linker |
[2] | |
Trastuzumab-Compound (lc) DAR 8 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P4 |
Trastuzumab-Compound (lc) DAR 8 linker |
[2] | |
Pertuzumab-Compound (lc) DAR 8 |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P4 |
Pertuzumab-Compound (lc) DAR 8 linker |
[2] | |
Trastuzumab-Compound (ld) DAR 1.6 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P1 |
Trastuzumab-Compound (ld) DAR 1.6 linker |
[2] | |
HuMy9-6IgG1-Compound (ld) DAR 8 |
huMy9-6 IgG1 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
huMy9-6IgG1-Compound (ld) DAR 8 linker |
[2] | |
Lintuzumab IgG1-Compound (ld) DAR 8 |
Lintuzumab |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Lintuzumab IgG1-Compound (ld) DAR 8 linker |
[2] | |
Trastuzumab-Compound (le) |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P1 |
Trastuzumab-Compound (le) linker |
[2] | |
Rituximab-Compound (le) |
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
NeoDegrader P1 |
Rituximab-Compound (le) linker |
[2] | |
Pertuzumab-Compound (le) |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P1 |
Pertuzumab-Compound (le) linker |
[2] | |
Trastuzumab-Compound (lf) |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P6 |
Trastuzumab-Compound (lf) linker |
[2] | |
Rituximab-Compound (lf) |
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
NeoDegrader P6 |
Rituximab-Compound (lf) linker |
[2] | |
Pertuzumab-Compound (lf) |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P6 |
Pertuzumab-Compound (lf) linker |
[2] | |
Trastuzumab-Compound (lg) |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P2 |
Trastuzumab-Compound (lg) linker |
[2] | |
Rituximab-Compound (lg) |
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
NeoDegrader P2 |
Rituximab-Compound (lg) linker |
[2] | |
Pertuzumab-Compound (lg) |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P2 |
Pertuzumab-Compound (lg) linker |
[2] | |
Trastuzumab-Compound (lh) |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P13 |
Trastuzumab-Compound (lh) linker |
[2] | |
Rituximab-Compound (lh) |
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
NeoDegrader P13 |
Rituximab-Compound (lh) linker |
[2] | |
Pertuzumab-Compound (lh) |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P13 |
Pertuzumab-Compound (lh) linker |
[2] | |
Trastuzumab-Compound (li) |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P1 |
Trastuzumab-Compound (li) linker |
[2] | |
Rituximab-Compound (li) |
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
NeoDegrader P1 |
Rituximab-Compound (li) linker |
[2] | |
Pertuzumab-Compound (li) |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P1 |
Pertuzumab-Compound (li) linker |
[2] | |
Trastuzumab-Compound (lj) |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P1 |
Trastuzumab-Compound (lj) linker |
[2] | |
Rituximab-Compound (lj) |
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
NeoDegrader P1 |
Rituximab-Compound (lj) linker |
[2] | |
Pertuzumab-Compound (lj) |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P1 |
Pertuzumab-Compound (lj) linker |
[2] | |
Trastuzumab-Compound (lk) |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P14 |
Trastuzumab-Compound (lk) linker |
[2] | |
Rituximab-Compound (lk) |
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
NeoDegrader P14 |
Rituximab-Compound (lk) linker |
[2] | |
Pertuzumab-Compound (lk) |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P14 |
Pertuzumab-Compound (lk) linker |
[2] | |
Trastuzumab-Compound (ll) |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P14 |
Trastuzumab-Compound (ll) linker |
[2] | |
Rituximab-Compound (ll) |
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
NeoDegrader P14 |
Rituximab-Compound (ll) linker |
[2] | |
Pertuzumab-Compound (ll) |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P14 |
Pertuzumab-Compound (ll) linker |
[2] | |
Trastuzumab-Compound (lm) |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P14 |
Trastuzumab-Compound (lm) linker |
[2] | |
Rituximab-Compound (lm) |
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
NeoDegrader P14 |
Rituximab-Compound (lm) linker |
[2] | |
Pertuzumab-Compound (lm) |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NeoDegrader P14 |
Pertuzumab-Compound (lm) linker |
[2] | |
Rituximab-Compound (la) DAR 4 |
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
NeoDegrader P1 |
Rituximab-Compound (la) linker |
[2] | |
HuAT12/5-Compound (Ia) |
HuAT12/5 |
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) |
NeoDegrader P1 |
HuAT12/5-Compound (Ia) linker |
[2] | |
Isatuximab-Compound (Ia) |
Isatuximab |
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) |
NeoDegrader P1 |
Isatuximab-Compound (Ia) linker |
[2] | |
Daratumumab-Compound (Ia) |
Daratumumab |
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) |
NeoDegrader P1 |
Daratumumab-Compound (Ia) linker |
[2] | |
Indatuximab-Compound (Ia) |
Indatuximab |
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) |
NeoDegrader P1 |
Indatuximab-Compound (Ia) linker |
[2] | |
Belantamab-Compound (Ia) |
Belantamab |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
NeoDegrader P1 |
Belantamab-Compound (Ia) linker |
[2] | |
Sacituzumab-Compound (Ia) |
Sacituzumab |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
NeoDegrader P1 |
Sacituzumab-Compound (Ia) linker |
[2] | |
U3-1784-Compound (Ia) |
U3-1784 |
Fibroblast growth factor receptor 4 (FGFR4) |
NeoDegrader P1 |
U3-1784-Compound (Ia) linker |
[2] | |
Cetuximab-Comound (Ia) |
Cetuximab |
Epidermal growth factor receptor (EGFR) |
NeoDegrader P1 |
Cetuximab-Comound (Ia) linker |
[2] | |
Olaratumab-Compound (Ia) |
Olaratumab |
Platelet-derived growth factor receptor alpha (PDGFRA) |
NeoDegrader P1 |
Olaratumab-Compound (Ia) linker |
[2] | |
Ontuxizumab-Compound (Ia) |
Ontuxizumab |
Endosialin (CD248) |
NeoDegrader P1 |
Ontuxizumab-Compound (Ia) linker |
[2] | |
Anti-CD33AB-Compound (Ia) |
Anti-CD33AB |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Anti-CD33AB-Compound (Ia) linker |
[1] | |
Anti-CD33AB-Compound (Ib) |
Anti-CD33AB |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Anti-CD33AB-Compound (Ib) linker |
[1] | |
Anti-CD33AB-Compound (Ic) |
Anti-CD33AB |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Anti-CD33AB-Compound (Ic) linker |
[1] | |
Anti-CD33AB-Compound (Ie) |
Anti-CD33AB |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Anti-CD33AB-Compound (Ie) linker |
[1] | |
Anti-CD33AB-Compound (Ih) |
Anti-CD33AB |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Anti-CD33AB-Compound (Ih) linker |
[1] | |
Gemtuzumab-Compound (Ia) |
Gemtuzumab |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Gemtuzumab-Compound (Ia) linker |
[1] | |
Gemtuzumab-Compound (Ib) |
Gemtuzumab |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Gemtuzumab-Compound (Ib) linker |
[1] | |
Gemtuzumab-Compound (Ic) |
Gemtuzumab |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Gemtuzumab-Compound (Ic) linker |
[1] | |
Gemtuzumab-Compound (Ih) |
Gemtuzumab |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Gemtuzumab-Compound (Ih) linker |
[1] | |
HuMy9-6-IgG4-S228P-Compound (Ia) |
huMy9-6-IgG4-S228P |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
huMy9-6-IgG4-S228P-Compound (Ia) linker |
[1] | |
HuMy9-6-IgG4-S228P-Compound (Ib) |
huMy9-6-IgG4-S228P |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
huMy9-6-IgG4-S228P-Compound (Ib) linker |
[1] | |
HuMy9-6-IgG4-S228P-Compound (Ic) |
huMy9-6-IgG4-S228P |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
huMy9-6-IgG4-S228P-Compound (Ic) linker |
[1] | |
HuMy9-6-IgG4-S228P-Compound (Ie) |
huMy9-6-IgG4-S228P |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
huMy9-6-IgG4-S228P-Compound (Ie) linker |
[1] | |
HuMy9-6-IgG4-S228P-Compound (Ih) |
huMy9-6-IgG4-S228P |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
huMy9-6-IgG4-S228P-Compound (Ih) linker |
[1] | |
Anti-CD33 AB1 Compound (Ia) |
Anti-CD33 AB1 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Anti-CD33 AB1 Compound (Ia) linker |
[3] | |
Anti-CD33 AB1 Compound (Ib) |
Anti-CD33 AB1 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Anti-CD33 AB1 Compound (Ib) linker |
[3] | |
Anti-CD33 AB1 Compound (Ic) |
Anti-CD33 AB1 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Anti-CD33 AB1 Compound (Ic) linker |
[3] | |
Anti-CD33 AB1 Compound (Id) |
Anti-CD33 AB1 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Anti-CD33 AB1 Compound (Id) linker |
[3] | |
Anti-CD33 AB1 Compound (Ie) |
Anti-CD33 AB1 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Anti-CD33 AB1 Compound (Ie) linker |
[3] | |
Anti-CD33 AB1 Compound (If) |
Anti-CD33 AB1 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P6 |
Anti-CD33 AB1 Compound (If) linker |
[3] | |
Anti-CD33 AB1 Compound (Ig) |
Anti-CD33 AB1 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P2 |
Anti-CD33 AB1 Compound (Ig) linker |
[3] | |
Anti-CD33 AB1 Compound (Ih) |
Anti-CD33 AB1 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Anti-CD33 AB1 Compound (Ih) linker |
[3] | |
Anti-CD33 AB1 Compound (Ii) |
Anti-CD33 AB1 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Anti-CD33 AB1 Compound (Ii) linker |
[3] | |
Anti-CD33 AB1 Compound (Ij) |
Anti-CD33 AB1 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P1 |
Anti-CD33 AB1 Compound (Ij) linker |
[3] | |
Anti-CD33 AB1 Compound (Ik) |
Anti-CD33 AB1 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P14 |
Anti-CD33 AB1 Compound (Ik) linker |
[3] | |
Anti-CD33 AB1 Compound (Il) |
Anti-CD33 AB1 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P14 |
Anti-CD33 AB1 Compound (Il) linker |
[3] | |
Anti-CD33 AB1 Compound (Im) |
Anti-CD33 AB1 |
Myeloid cell surface antigen CD33 (CD33) |
NeoDegrader P14 |
Anti-CD33 AB1 Compound (Im) linker |
[3] |
References
